EP0979309A4 - Oligonucleotides presentant une meilleure biodisponibilite - Google Patents

Oligonucleotides presentant une meilleure biodisponibilite

Info

Publication number
EP0979309A4
EP0979309A4 EP98920076A EP98920076A EP0979309A4 EP 0979309 A4 EP0979309 A4 EP 0979309A4 EP 98920076 A EP98920076 A EP 98920076A EP 98920076 A EP98920076 A EP 98920076A EP 0979309 A4 EP0979309 A4 EP 0979309A4
Authority
EP
European Patent Office
Prior art keywords
oligonucleotides
enhanced bioavailability
alimentary delivery
oligonucleotide
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP98920076A
Other languages
German (de)
English (en)
Other versions
EP0979309A1 (fr
Inventor
Nicholas M Dean
C Frank Bennett
Brett P Monia
Kenneth Draper
Kevin P Anderson
Brenda F Baker
David J Ecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of EP0979309A1 publication Critical patent/EP0979309A1/fr
Publication of EP0979309A4 publication Critical patent/EP0979309A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Compositions et procédés pour l'administration par la voie digestive d'oligonucléotides à un animal, dont l'homme. La présente invention concerne des modifications apportées à ces oligonucléotides, qui favorisent l'assimilation après ingestion.
EP98920076A 1997-04-30 1998-04-30 Oligonucleotides presentant une meilleure biodisponibilite Ceased EP0979309A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US847151 1993-02-09
US84715197A 1997-04-30 1997-04-30
PCT/US1998/008798 WO1998049348A1 (fr) 1997-04-30 1998-04-30 Oligonucleotides presentant une meilleure biodisponibilite

Publications (2)

Publication Number Publication Date
EP0979309A1 EP0979309A1 (fr) 2000-02-16
EP0979309A4 true EP0979309A4 (fr) 2000-10-18

Family

ID=25299899

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98920076A Ceased EP0979309A4 (fr) 1997-04-30 1998-04-30 Oligonucleotides presentant une meilleure biodisponibilite

Country Status (6)

Country Link
EP (1) EP0979309A4 (fr)
JP (1) JP2000514095A (fr)
KR (1) KR20010020370A (fr)
AU (1) AU738352B2 (fr)
CA (1) CA2286396C (fr)
WO (1) WO1998049348A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69834038D1 (de) 1997-07-01 2006-05-18 Isis Pharmaceutical Inc Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre
EP1080225A4 (fr) * 1998-05-21 2004-02-04 Isis Pharmaceuticals Inc Compositions et methodes d'administration aux poumons d'acides nucleiques
ES2272069T3 (es) 1998-05-22 2007-04-16 Ottawa Health Research Institute Metodos y productos para inducir inmunidad en mucosas.
JP2002537343A (ja) * 1999-02-23 2002-11-05 アイシス・ファーマシューティカルス・インコーポレーテッド 多重粒子製剤
US6168950B1 (en) * 1999-07-23 2001-01-02 Isis Pharmaceuticals, Inc. Antisense modulation of MEKK1 expression
US6677445B1 (en) 1999-08-27 2004-01-13 Chiron Corporation Chimeric antisense oligonucleotides and cell transfecting formulations thereof
DE60038220T2 (de) * 1999-08-27 2009-03-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Chimerische antisense-oligonukleotide und zelltransfektions-zusammensetzungen davon
EP1414841B1 (fr) 2001-07-10 2012-11-14 Lakewood-Amedex, Inc Compositions pharmacologiques contenant des oligonucleotides et leur utilisation
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
PT2364360T (pt) 2008-11-13 2017-06-27 Nogra Pharma Ltd Composições em sentido reverso e métodos de as fabricar e utilizar

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0626387A1 (fr) * 1993-05-12 1994-11-30 Ciba-Geigy Ag Nucléosides et oligonucléotides contenant des groupes d'éther sur les positions 2'
WO1995002069A1 (fr) * 1993-07-09 1995-01-19 Isis Pharmaceuticals, Inc. Modulation oligonucleotidique de la proteine kinase c
WO1996012497A1 (fr) * 1994-10-25 1996-05-02 Hybridon, Inc. Utilisation d'oligonucleotides substitues en 2' pour freiner l'expression d'un gene
WO1997029780A1 (fr) * 1996-02-14 1997-08-21 Isis Pharmaceuticals, Inc. Oligonucleotides methoxyethoxy modulant l'expression de la proteine kinase c

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214135A (en) * 1991-08-30 1993-05-25 Chemgenes Corporation N-protected-2'-O-methyl-ribonucleosides and N-protected 2'-O-methyl-3'-cyanoethyl-N-,N-diisopropyl phosphoramidite ribonucleosides
ATE247971T1 (de) * 1995-08-01 2003-09-15 Novartis Erfind Verwalt Gmbh Liposomale oligonukleotidzusammensetzungen

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0626387A1 (fr) * 1993-05-12 1994-11-30 Ciba-Geigy Ag Nucléosides et oligonucléotides contenant des groupes d'éther sur les positions 2'
WO1995002069A1 (fr) * 1993-07-09 1995-01-19 Isis Pharmaceuticals, Inc. Modulation oligonucleotidique de la proteine kinase c
WO1996012497A1 (fr) * 1994-10-25 1996-05-02 Hybridon, Inc. Utilisation d'oligonucleotides substitues en 2' pour freiner l'expression d'un gene
WO1997029780A1 (fr) * 1996-02-14 1997-08-21 Isis Pharmaceuticals, Inc. Oligonucleotides methoxyethoxy modulant l'expression de la proteine kinase c

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MARTIN P: "38. EIN NEUER ZUGANG ZU 2'-O-ALKYLRIBONUCLEOSIDEN UND EIGENSCHAFTEN DEREN OLIGONUCLEOTIDE", HELVETICA CHIMICA ACTA,CH,VERLAG HELVETICA CHIMICA ACTA. BASEL, vol. 78, 1995, pages 486 - 504, XP000857415, ISSN: 0018-019X *
See also references of WO9849348A1 *

Also Published As

Publication number Publication date
EP0979309A1 (fr) 2000-02-16
CA2286396A1 (fr) 1998-11-05
JP2000514095A (ja) 2000-10-24
KR20010020370A (ko) 2001-03-15
AU7272398A (en) 1998-11-24
WO1998049348A1 (fr) 1998-11-05
AU738352B2 (en) 2001-09-13
CA2286396C (fr) 2010-07-06

Similar Documents

Publication Publication Date Title
MXPA01004876A (es) Producto comestible refrescante de aliento.
ZA200200743B (en) Preserved pharmaceutical formulations.
ZA200300791B (en) Confectionery product containing active ingredients.
GB9909711D0 (en) Mousse forming hair treatment composition
HK1016472A1 (en) Activated protein c formulations.
ZA982253B (en) Therapeutic compositions.
ZA993338B (en) Pharmaceutical formulations.
HK1030753A1 (en) Fracture healing using pthrp analogs.
ZA200202996B (en) Hair treatment compositions comprising particulate substances.
HK1033278A1 (en) Pharmaceutical preparation for use in anti-asthma therapy.
ZA200202476B (en) Tissue products containing antiviral agents which are mild to the skin.
HK1047584A1 (en) Benzopyrans and benzoxepines, pharmaceutical compositions comprising them and preparation process.
ZA200006169B (en) Edible fat based flakes.
EP1435982A4 (fr) Systeme d'administration d'ingredients pharmaceutiques, nutritionnels et cosmetiques
MXPA01012478A (es) Formulaciones farmaceuticas mejoradas.
EP0979309A4 (fr) Oligonucleotides presentant une meilleure biodisponibilite
HK1040980A1 (zh) 聯苯磺酰基氨基氰、其製備方法及其作為藥物的用途
ZA200109348B (en) Noninvasive genetic immunization, expression products therefrom, and uses thereof.
PL349393A1 (en) Sulphonyloxazolamines as therapeutic active ingredients
HK1022853A1 (en) Pharmaceutical compositions.
HK1040488A1 (en) Pharmaceutical formulations.
EP1129725A3 (fr) Conjugués de oligonucléotides
WO2001014415A3 (fr) Gènes egfh2 et produits géniques
AU6082800A (en) Edible animal muscle protein gels
IT1295647B1 (it) Apparecchiatura per incartare prodotti di medie dimensioni, in particolare prodotti dolciari.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ECKER, DAVID, J.

Inventor name: BAKER, BRENDA, F.

Inventor name: ANDERSON, KEVIN, P.

Inventor name: DRAPER, KENNETH

Inventor name: MONIA, BRETT, P.

Inventor name: BENNETT, C., FRANK

Inventor name: DEAN, NICHOLAS, M.

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12Q 1/68 A, 7C 12N 15/00 B, 7C 12N 15/63 B, 7C 12N 5/06 B, 7C 07H 21/00 B, 7C 07H 21/04 B, 7A 61K 48/00 B, 7A 61K 31/70 B

A4 Supplementary search report drawn up and despatched

Effective date: 20000830

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030124

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ISIS PHARMACEUTICALS, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20050401